Methylnissolin (Astrapterocarpan) is an osteoclast inhibitor with anti-inflammatory, neuroprotective and antioxidant activities. Methylnissolin downregulates the activation of the MAPK and PI3K/AKT pathways, inhibits the phosphorylation of MAPK1 and AKT1 , and blocks PDGF-BB -induced phosphorylation of ERK1/2 . Methylnissolin reduces the expression and secretion of proinflammatory mediators, decreases intracellular ROS levels, upregulates antioxidant enzymes , and downregulates osteoclastogenesis markers. Methylnissolin is applicable to research related to ischemic stroke, osteoporosis, cardiovascular diseases, skin aging, etc.
Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Oxidative Stress and Inflammation | Products > Disease Areas > Cerebrovascular Disease | Products > Disease Areas > Mineral Metabolism | Products > Disease Areas > Cellular Senescence | Products > Disease Areas > Ischemic Stroke | Products > Disease Areas > Osteoporosis | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Research Areas > Neurological Disease | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > PDGFR | Products > Signaling Pathways > ERK
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.